MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer's Disease and Dementia

Stock Information for MediPharm Labs Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MediPharm Labs Corp.

MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.